Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pasithea TherapeuticsKTTA -3.89%29 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates KTTA with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 950 Biotechnology companies, Pasithea Therapeutics ranks worse than 105263.05% on this metric.
The historical rank and industry rank for Pasithea Therapeutics's FCF Margin % or its related term are showing as below:
During the past 6 years, the highest FCF Margin % of Pasithea Therapeutics was -21306.67%. The lowest was -21306.67%. And the median was -21306.67%.
KTTA's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -81.28 * Ranked among companies with meaningful FCF Margin % only.
Pasithea Therapeutics FCF Margin % Related Terms
Pasithea Therapeutics FCF Margin % Historical Data
* Premium members only.
The historical data trend for Pasithea Therapeutics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Pasithea Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pasithea Therapeutics FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pasithea Therapeutics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Pasithea Therapeutics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pasithea Therapeutics (KTTA) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Pasithea Therapeutics and its competitors. According to the industry distribution chart, Pasithea Therapeutics ranks #999999 out of 950 companies in the Biotechnology industry.
Is Pasithea Therapeutics' FCF Margin % too high?
Pasithea Therapeutics' current FCF Margin % is 0.00%. Based on the distribution chart, Pasithea Therapeutics ranks #999999 out of 950 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pasithea Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Pasithea Therapeutics' FCF Margin % compare to CELU and GRTX?
According to the Biotechnology industry distribution chart, Pasithea Therapeutics ranks #999999 out of 950 companies for FCF Margin %. This places Pasithea Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Pasithea Therapeutics and its competitors. Pasithea Therapeutics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pasithea Therapeutics stock overvalued right now?
Pasithea Therapeutics (KTTA) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Pasithea Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Pasithea Therapeutics (KTTA), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
29GF Score
Get the complete analysis for KTTA
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KTTA has been successfully added to your 
